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Background/purpose: Complications from biliary drainage in biliary tract cancer (BTC) may influence
the relative dose intensity of chemotherapy or increase adverse events during chemotherapy. BT22 was
a randomized phase II trial, the results of which were consistent with those of a phase III trial in
non-Japanese that demonstrated the effectiveness of gemcitabine plus cisplatin combination therapy
(GC) in BTC. The purpose of this exploratory analysis of the BT22 study was to identify the possible
effects of biliary drainage on the efficacy and safety of GC or gemcitabine monotherapy (G).
Patients and Methods: The 83 BTC patients who received GC or G in BT22 were retrospectively
analysed in two subgroups dependent upon whether biliary drainage was performed before study entry.
Efficacy and safety of treatment (GC vs. G) were compared in these two groups.
Results: The GC arm had a higher 1-year survival rate and longer median survival time (MST) than the
G arm independent of prior biliary drainage. Patients in the drainage subgroup developed cholangitis
more frequently, however, the frequency of grade 3/4 adverse events did not differ between the treatment
regimens with/without drainage.
Conclusions: Biliary drainage before chemotherapy did not affect the therapeutic efficacy or tolerability
of chemotherapy using G or GC.
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Introduction
Biliary tract cancer (BTC), while relatively rare in Western coun-
tries, is more common in Japan where it is the sixth leading cause
of cancer death with approximately 17 000 deaths every year.1 The
mortality caused by BTC in Japan is higher than any other
country, and far exceeds all Western countries.2
Developing an effective BTC treatment has become a high pri-
ority for Japan. At present the only curative treatment is surgical
resection, and although an increasing number of patients undergo
surgery each year, outcomes have met with only a varying degree
of success. Patients with unresectable disease can only be managed
with chemotherapy and supportive care for palliation of disease
including biliary decompression. However, prognosis remains
extremely poor in these patients.
No standard chemotherapy for BTC has been established.Many
clinical trials of systemic chemotherapy have been conducted in
BTC patients, but most of these were phase II trials that had small
sample sizes and lacked a control group because of the rarity and
heterogeneity of BTC. In 2009, the results of a phase III study
of gemcitabine plus cisplatin (GC) vs. gemcitabine monotherapy
(G) conducted in the United Kingdom (ABC-02 Study) were
reported.3 This previous study included 410 patients and is the
largest clinical trial to be conducted in this field. The GC arm had
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a significantly better median survival time (MST) [11.7 months
(95% confidence interval (CI) 9.5 to 14.3) vs. 8.1 months (95% CI
7.1 to 8.7); P < 0.001] and progression-free survival (PFS) [8.0
months (95% CI 6.6 to 8.6) vs. 5.0 months (95% CI 4.0 to 5.9);
P < 0.001] than the G arm. A comparison of grade 3 and 4
toxicities showed that the GC combination added little toxicity.
From the results of the ABC-02 study, GC was recognized as the
standard of care for the treatment of advanced BTC. A random-
ized phase II study comparing GC and G was also conducted in
Japan (BT22 study; Clinical Trial.gov Identifier NCT00380588).
Median survival time [11.2 vs. 7.7 months; hazard ratio (HR) 0.69
(95% CI 0.42 to 1.13)] and PFS [5.8 vs. 3.7 months; HR 0.66 (95%
CI 0.41 to 1.05)] were similar to the results seen in the ABC-02
study confirming the status of GC as the worldwide standard.4
For patients with unresectable disease, biliary decompression is
often required if chemotherapy is contemplated.5 Usually, biliary
obstruction will be managed by percutaneous or endoscopic
drainage rather than a surgical approach because of the presence
of incurable disease and high operative risk. However, complica-
tions resulting from insufficient biliary drainage,morbidities such
as obstructive jaundice, cholangitis, and sepsis, often require that
chemotherapy be interrupted or discontinued.6 Obstructive jaun-
dice may impact on prognosis by necessitating dose modification
of chemotherapy or by complications as a consequence of biliary
obstruction.
In the present study, we analysed the data from the BT22 study
conducted in Japan to determine the impact of biliary drainage on
the efficacy and adverse events associated with gemcitabine-based
chemotherapy.
Patients and methods
Patients
This analysis included all patients who received at least one dose of
study treatment in the BT22 study, a multicentre study conducted
at nine medical institutions in Japan. From September 2006 to
October 2008, 84 BTC patients were enrolled. The patients were
randomized to either the GC arm [a weekly intravenous (i.v.)
infusion of cisplatin 25 mg/m2 followed by gemcitabine
1000 mg/m2 for 2 weeks, followed by dose suspension at the third
week, repeated as one course] or the G arm (weekly i.v. infusion of
gemcitabine 1000 mg/m2 for 3 weeks followed by dose suspension
at the fourth week, repeated as one course). Randomization was
stratified by primary tumour site (gallbladder cancer or other
BTC) and the presence or absence of a primary tumour. One
patient in the GC arm was discontinued before the start of the
study treatment for deterioration of a general condition caused by
another complication, so the analysis was conducted with 41 GC
arm patients and 42 G arm patients (Fig. 1).
The specific criteria for study eligibility have been reported
previously4 and are only summarized here:
• patients with unresectable locally advanced or metastatic intra-
hepatic bile duct cancer, extrahepatic bile duct cancer, gallblad-
der cancer, or ampullary carcinoma that is histologically or
cytologically confirmed adenocarcinoma (including adenos-
quamous carcinoma);
• patients with at least one measurable lesion;
• patients with no prior chemotherapy;
• patients with a performance status of 0 or 1;
Randomized
(n = 84)
Stratification factors
1. Primary tumour site
   (gallbladder, other BTC)
2. Presence of primary tumor
GC arm (n = 42) G arm (n = 42)
Not treated (n = 1)
Deterioration of general condition
before study treatment
G arm: treatedGC arm: treated
(n = 41)
Cisplation 25 mg/m2 +
Gemcitabine 1000 mg/m2
on days 1, 8 q21d
Gemcitabine 1000 mg/m2
on days 1, 8, 15 q28d
(n = 42)
Figure 1 Patient disposition of the BT22 Study. BTC, biliary tract cancer; G arm, gemcitabine monotherapy; GC arm, combination therapy
with gemcitabine and cisplatin
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• patients with an estimated life expectancy of more than 3
months; and
• patients with adequate organ function (e.g. bone marrow, liver
and kidney).
Methods
The BT22 study was a randomized study that compared patients
from two arms: GC vs. G.
Patients with obstructive jaundice had to achieve a certain
degree of jaundice reduction with biliary drainage before study
entry (i.e. total bilirubin was three times the upper limit of normal
or less). The protocol contained no specific provisions about
biliary drainage. The approach (endoscopic or percutaneous tran-
shepatic), drainage type (internal biliary drainage or external
biliary drainage) and stent material (plastic stent or metallic stent)
could be decided by the investigator. The primary endpoint was
1-year survival rate. Sample size was calculated by the method
proposed by Simon et al.7 The 83 treated patients were retrospec-
tively analysed and classified into subgroups of patients who had
undergone biliary drainage before the start of the study (BD sub-
group) and patients who had not (non-BD subgroup) to compare
the efficacy and safety of the treatment regimens (GC vs. G arms).
Progression-free survival and overall survival (OS) curves were
constructed using the Kaplan–Meier method, and estimates of
median OS and the respective 95% CIs were calculated from the
Kaplan–Meier estimates. Cox’s proportional hazard model was
used to estimate the HR. Adverse events were graded according to
the Common Terminology Criteria for Adverse Events, version 3.0
(CTCAE v. 3.0). A multivariate Cox proportional hazard model
was used to identify prognostic factors.
Results
Of the 83 patients treated in the BT22 study, 34 were in the BD
sugroup (16 in the GC arm and 18 in the G arm) and 49 were in
the non-BD subgroup (25 in the GC arm and 24 in the G arm).
Table 1 shows patient baseline characteristics.More of the patients
in the BD subgroup (n = 34) had a primary tumour [GC: (14/16)
87.5%, G: (18/18) 100%], whereas the percentages of patients in
the non-BD subgroup (n = 49) without a primary tumour were
relatively higher [GC: (9/25) 36.0%, G: (11/24) 45.8%]. However,
no substantial imbalances were noted between the two subgroups
in gender, age or primary tumour site.
Efficacy
Efficacy data for the subgroups are shown in Table 2 and
Fig. 2. In the BD subgroup, a comparison of OS in the GC and
G arms showed 1-year survival of 40.9% vs. 27.8% and MST of
11.3 vs. 8.1 months [HR of 0.59 (95% CI 0.27 to 1.30)], respec-
tively. In the non-BD subgroup, a comparison between the
GC and C arms showed 1-year survival rate of 37.8% vs. 33.3%
and MST of 9.6 vs. 7.5 months [HR of 0.76 (95% CI 0.40 to
1.45)], respectively.
Table 1 Patient characteristics at baseline
Characteristics BD (n = 34) Non-BD (n = 49)
n (%) n (%)
GC arm (n = 16) G arm (n = 18) GC arm (n = 25) G arm (n = 24)
Gender
Male 7 (43.8) 9 (50.0) 11 (44.0) 12 (50.0)
Female 9 (56.3) 9 (50.0) 14 (56.0) 12 (50.0)
Age
Median (years) 64.5 65.5 65.0 68.5
PS
0 13 (81.3) 12 (66.7) 21 (84.0) 16 (66.7)
1 3 (18.8) 6 (33.3) 4 (16.0) 8 (33.3)
Primary tumour site
Gallbladder 6 (37.5) 9 (50.0) 9 (36.0) 8 (33.3)
Non-gallbladder 10 (62.5) 9 (50.0) 16 (64.0) 16 (66.7)
Presence of a primary tumour
Present 14 (87.5) 18 (100.0) 16 (64.0) 13 (54.2)
Absent 2 (12.5) 0 (0.0) 9 (36.0) 11 (45.8)
Extent of disease
Locally advanced 5 (31.3) 7 (38.9) 0 (0.0) 1 (4.2)
Metastatic 11 (68.8) 11 (61.1) 25 (100.0) 23 (95.8)
BD, biliary drainage; G arm, gemcitabine monotherapy; GC arm, combination therapy with gemcitabine and cisplatin; PS, performance status.
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Subgroup analysis results based on HRs for OS by biliary drain-
age, performance status (PS), primary tumour site, presence of
primary tumour and extent of disease are shown in Fig. 3. Hazard
ratios (GC vs. G) for OS were less than one in every subgroup.
Safety
Adverse events observed in the GC and G arms with a frequency of
at least 30% in the BT22 study have been reported.4 In this analy-
sis, the frequency of grade 3 and 4 events for the most common
adverse events (frequency 30%) in the BD subgroup was com-
pared with that in the non-BD subgroup (Table 3). Events in the
BD subgroup that were more common in the GC arm were hae-
moglobin decrease (43.8% vs. 5.6%), thrombocytopenia (37.5%
vs. 5.6%) and red blood cell decrease (37.5% vs. 5.6%). Events in
the non-BD subgroup that were more common in the GC arm
were leukopaenia (32.0% vs. 12.5%), neutoropenia (64.0% vs.
33.3%), and thrombocytopaenia (40.0% vs. 8.3%). There were no
significant differences in the incidence of non-haematological
events between the GC and G arms in either the BD or non-BD
subgroup.
Although the incidence of cholangitis was higher in the BD
subgroup than in the non-BD subgroup, the ratio of cholangitis in
the GC arm to that in the G arm was not appreciably different in
each of the BD and non-BD subgroups. For the BD subgroup, the
incidence of Grade 3 and 4 cholangitis in the G arm was relatively
higher than that in the GC arm (Table 4).
Prognostic factors
A multivariate Cox’s proportional hazard model was used with
the following six factors: biliary drainage, PS (0 vs. 1), primary
tumour site (gallbladder vs. non-gallbladder), the presence of a
primary tumour (present vs. absent), extent of disease (locally
advanced vs. metastatic) and chemotherapy regimen (GC arm vs.
G arm) (Table 5). The HR of the GC arm to the G arm was 0.72
[95% CI 0.44 to 1.20] after multivariate adjustment for several
variables. The primary tumour site of non-gallbladder [HR of
gallbladder vs. non-gallbladder 1.72 (95% CI 1.01 to 2.93)] and
the absence of a primary tumour [HR of presence vs. absence 2.79
(95% CI 1.40 to 5.56)] were significantly related to a longer OS.
Biliary drainage was suggested to have favourable clinical rel-
evance [HR 0.72 (95% CI 0.39 to 1.32)], as well as PS 0 and locally
advanced disease.
Discussion
Many studies on unresectable BTC retrospectively investigated
whether biliary drainage should be performed endoscopically
or with a percutaneous transhepatic approach,8,9 and whether
a plastic or metallic stent should be used.10–15 Several of the
few prospective studies conducted have stent patency or
complication-free survival as a primary endpoint. However, only a
few of those have considered the impact of drainage on chemo-
therapy efficacy or adverse events. This analysis represents an
important exploratory investigation of the impact of biliary
drainage on chemotherapy efficacy in the BT22 study which was a
prospectively controlled study.
Insufficient biliary drainage leads to problems during chemo-
therapy, such as recurrent obstructive jaundice with or without
cholangitis, which in turn often results in suspension or discon-
tinuation of chemotherapy. In the BT22 study, the incidence of
cholangitis during initial chemotherapy in the GC and G arms in
the BD subgroup was higher than that in the respective arms of
the non-BD subgroup. Although the profiles of grade 3 and 4
non-haematological adverse events in the GC and G arms did not
differ, haematological toxicities were slightly more severe in the
GC arm. GC therapy is expected to lead to an increased incidence
of cholangitis or progression to severe cholangitis in patients
undergoing biliary drainage who are at high risk of cholangitis
mainly because the regimen has a more severe haematological
toxicity profile than G. These events could undermine the efficacy
of GC therapy.
In the BD subgroup, however, MST in the GC and G arms were
11.3 vs. 8.1 months, respectively, with an HR of 0.59 (95% CI 0.27
to 1.30). Median survival time in the GC arm was longer than
MST in the G arm. As with adverse events overall, grade 3 and 4
adverse events in the BD subgroup were slightly more severe in the
Table 2 Overall survival and progression-free survival with or without biliary drainage by treatment arm
BD (n = 34) Non-BD (n = 49)
GC arm (n = 16) G arm (n = 18) GC arm (n = 25) G arm (n = 24)
Overall survival
1-year survival rate 40.9% 27.8% 37.8% 33.3%
Median survival time (months) 11.3 8.1 9.6 7.5
Hazard ratio (95% confidence interval) 0.588 (0.266–1.301) 0.758 (0.397–1.447)
Progression-free survival
6-month progression-free survival 53.3% 27.8% 43.7% 27.5%
Median progression-free survival (months) 7.1 3.9 4.5 3.3
Hazard ratio (95% confidence interval) 0.479 (0.222–1.032) 0.748 (0.407–1.374)
BD, biliary drainage; G arm, gemcitabine monotherapy; GC arm, combination therapy with gemcitabine and cisplatin.
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Probability
1.0
0.8
0.6
0.0
At risk
  GC arm
G arm
0
16
18
15
13
Survival time (months)
6
5
2
2
3 6 9
BD
12 15 18 21 24
0.2
0.4
Probability Non-BD
1.0
0.8
0.6
0.0
At risk
  GC arm
G arm
0
25
24
20
16
GC arm, G Arm
Survival time (months)
9
8
3
2
3 6 9 12 15 18 21 24
0.2
0.4
Figure 2 Survival curves in the BD subgroup (a) and non-BD subgroup (b) by the treatment arm. Solid line (—) indicates the GC arm and the
broken line (---) the G arm. BD, biliary drainage; G arm, gemcitabine monotherapy; GC arm, combination therapy with gemcitabine and
cisplatin
Subgroup
Biliary
drainage Non-BD
BD
HR*
0.588
0.4006
0.1902
0.3520
0.3344
0.6746
0.1097
0.2525
0.4757
0.3891
0.2181
0 0.5 1 1.5 2 2.5 3
0.758
0.759
0.592
0.852
0.578
0.722
0.602
0.591
0.715
P-value hazard ratio with 95% confidence interval
Gallbladder
Non-gallbladder
Present
Absent
Locally advanced
Metastatic
0
1
PS
Primary
tumour site
Presence of 
primary tumour
Extent of
disease
Figure 3 Hazard ratios for overall survival by patient baseline characteristics. HR*, hazard ratio of the combination therapy with gemcitabine
and cisplatin (GC) arm to the gemcitabine monotherapy (G) arm
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GC arm than in the G arm, but no particularly frequent events
were encountered. In addition, patients with biliary drainage in
the G arm had a relatively increased incidence of grade 3 and 4
cholangitis, possibly as a result of a lack of efficacy and inferior
biliary drainage.Although careful monitoring of cholangitis is still
needed, the above findings indicate GC to be an appropriate stan-
dard chemotherapy for unresectable BTC in both patients with
and without biliary drainage.
Because this analysis was a retrospective investigation of the
BT22 study, several biases could arise after this retrospective
approach. Although the biases cannot be completely circum-
vented using a multivariate Cox’s proportional hazard model,
the results adjusted with other prognostic factors suggested that
biliary drainage would not have a negative impact on the anti-
cancer effect of chemotherapy. The results suggested that base-
line biliary drainage did not adversely impact patient prognosis.
The presence of a primary tumour (present vs. absent) and
primary tumour site (gallbladder vs. non-gallbladder) had the
greatest impact on the prognosis, which suggests that the strati-
fication factors of the present study were appropriately selected.
Table 3 Incidence of grade 3 or 4 events among most common adverse eventsa
Most common adverse events BD (n = 34) Non-BD (n = 49)
n (%) n (%)
GC arm (n = 16) G arm (n = 18) GC arm (n = 25) G arm (n = 24)
Hematologic
WBC count decreased 4 (25.0) 5 (27.8) 8 (32.0) 3 (12.5)
Neutrophil count decreased 7 (43.8) 8 (44.4) 16 (64.0) 8 (33.3)
RBC decreased 6 (37.5) 1 (5.6) 8 (32.0) 5 (20.8)
Haemoglobin decreased 7 (43.8) 1 (5.6) 8 (32.0) 6 (25.0)
Haematocrit decreased 1 (6.3) 0 (0.0) 1 (4.0) 0 (0.0)
Platelet count decreased 6 (37.5) 1 (5.6) 10 (40.0) 2 (8.3)
Non-haematological
Anorexia 0 (0.0) 0 (0.0) 0 (0.0) 2 (8.3)
Nausea 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Vomiting 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Constipation 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Diarrhoea 1 (6.3) 0 (0.0) 0 (0.0) 0 (0.0)
Fatigue 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.2)
Pyrexia 0 (0.0) 2 (11.1) 0 (0.0) 0 (0.0)
Weight decreased 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AST increased 3 (18.8) 5 (27.8) 4 (16.0) 2 (8.3)
ALT increased 4 (25.0) 5 (27.8) 6 (24.0) 2 (8.3)
GGT increased 6 (37.5) 7 (38.9) 6 (24.0) 8 (33.3)
LDH increased 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
ALP increased 1 (6.3) 3 (16.7) 2 (8.0) 4 (16.7)
Blood sodium decreased 4 (25.0) 2 (11.1) 3 (12.0) 2 (8.3)
C-reactive protein increased 0 (0.0) 2 (11.1) 0 (0.0) 1 (4.2)
aMost common, incidence 30% of all grades; events were graded according to CTCAE v3.0.
AST, aspartate aminotransferase; ALP, alkaline phosphatase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; BD, biliary drainage;
G arm, gemcitabine monotherapy; GC arm, combination therapy with gemcitabine and cisplatin.
Table 4 Incidence of cholangitis with or without biliary drainage by treatment arm
BD (n = 34) Non-BD (n = 49)
n (%) n (%)
GC arm (n = 16) G arm (n = 18) GC arm (n = 25) G arm (n = 24)
Cholangitis (all grades) 5 (31.3) 7 (38.9) 2 (8.0) 3 (12.5)
Cholangitis ( grade 3) 2 (12.5) 5 (27.8) 0 (0.0) 1 (4.2)
BD, biliary drainage; G arm, gemcitabine monotherapy; GC arm, combination therapy with gemcitabine and cisplatin.
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As the BT22 study was conducted to compare chemotherapy
regimens, the data available for investigating biliary drainage, e.g.
the site of bile duct obstruction, the approach (endoscopic or
percutaneous transhepatic) and the stent material (plastic stent or
metallic stent), were limited. Thus, patient baseline characteristics
varied substantially. A detailed subgroup analysis on biliary drain-
age was unfortunately infeasible with the limited sample size of
the study. Moreover, this analysis was conducted to investigate the
impact of whether or not biliary drainage was performed before
starting chemotherapy, and patients requiring biliary drainage
during chemotherapy were consequently included in the non-BD
subgroup. Data on adverse events occurring during the primary
treatment period are available, but adverse events occurring with
more advanced cancer in secondary and subsequent treatments
were not investigated. No definite conclusions about the relation-
ship of biliary drainage to chemotherapy may therefore be drawn
based on the findings of this analysis alone.
Conclusion
In this analysis, GC combination therapy was safely administered
and the therapeutic efficacy of the GC arm was maintained in
patients with or without biliary drainage. The presence or absence
of biliary drainage was not found to impact the efficacy or adverse
events in each treatment arm for unresectable BTC. Based on
these results, it appears that adequate efficacy with gemcitabine-
based chemotherapy can be expected in patients with BTC even
with biliary drainage.
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